Factor V Leiden (F5) R506Q Mutation
Ordering Recommendation

Order to detect factor V Leiden variant.

Polymerase Chain Reaction/Fluorescence Monitoring
2-5 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B). 
Specimen Preparation
Transport 3 mL whole blood. (Min: 1 mL) 
Storage/Transport Temperature
Unacceptable Conditions
Plasma or serum; collection of specimen in sodium heparin tubes. 
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable 
Reference Interval
Negative: This sample is negative for factor V Leiden, R506Q mutation.
Interpretive Data
Background Information for Factor V Leiden (F5) R506Q Mutation
Factor V Leiden mutation is the most common cause of inherited thrombophilia and accounts for over 90 percent of activated protein C resistance. The expression of Factor V Leiden thrombophilia is impacted by coexisting genetic thrombophilic disorders, acquired thrombophilic disorders (malignancy, hyperhomocysteinemia, high factor VIII levels), and circumstances including: pregnancy, oral contraceptive use, hormone replacement therapy, selective estrogen receptor modulators, travel, central venous catheters, surgery, transplantation and advanced age.
Approximately 5 percent of Caucasians, 2 percent of Hispanics, 1 percent of African Americans and Native Americans and 0.5 percent of Asians are heterozygous; homozygosity occurs in 1 in 5000 individuals.
Incomplete autosomal dominant.
Lifetime risk of thrombosis is 10 percent for heterozygotes and 80 percent for homozygotes.
A deleterious F5 gene mutation R506Q (1691G>A). Note: Standardized nomenclature for the Factor V Leiden mutation is c.1601G>A (p.Arg534Gln).
Clinical Sensitivity and Specificity:
99 percent.
Polymerase chain reaction and fluorescence monitoring.
Analytical Sensitivity and Specificity:
99 percent.
Diagnostic errors can occur due to rare sequence variations. F5 gene mutations, other than R506Q, will not be detected.

Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

This test is not recommended for nonsymptomatic patients under 18 years of age.
Hotline History
View Hotline History
Component Test Code*Component Chart NameLOINC
0097720Factor V Leiden (F5) R506Q Mutation21668-9
2001387FACV Specimen31208-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Activated protein C resistance mutation
  • APC Resistance Mutation Detection
  • FVL R506Q mutation testing